At long last luvelta-T is shelved, and Sutro seeks a new focus.
ApexOnco Front Page
Recent articles
The Japanese group licenses sapablursen from Ionis for $280m.
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
The company reckons it’s got what it takes to hit the right member of the FGFR family.
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
First-in-human study starts include radioligands from Akiram and Philogen.